ANAB NASDAQ
AnaptysBio, Inc.
1W: -2.9%
1M: +12.8%
3M: +11.5%
YTD: +34.4%
1Y: +186.3%
3Y: +224.3%
5Y: +131.5%
$59.71
-0.70 (-1.16%)
Weekly Expected Move ±13.3%
$46
$55
$63
$72
$80
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year High – Time to Buy?
AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
GSK subsidiary wins dismissal of AnaptysBio anticipatory breach claim
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of “Moderate Buy” by Analysts
AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen - MarketBeat
ANAB Stock Jumps As Spin-Off Creates High-Margin Royalty Play - timothysykes.com
Spin-off leaves AnaptysBio (NASDAQ: ANAB) with 2025 pro forma profit - Stock Titan
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim - Stock Titan
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
Assessing AnaptysBio (ANAB) Valuation As It Shifts To A Royalty Focus After Spinning Off Operations - simplywall.st
AnaptysBio (NASDAQ: ANAB) CEO disposes of 11,000 stock options - Stock Titan
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
AnaptysBio (ANAB) director Orwin updates stock options after separation - Stock Titan
[Form 4] ANAPTYSBIO, INC Insider Trading Activity - Stock Titan
Option adjustments for AnaptysBio (NASDAQ: ANAB) director Renton Hollings - Stock Titan
AnaptysBio (ANAB) CEO adjusts and receives new stock option grants - Stock Titan
ANAB Maintained by Barclays -- Price Target Lowered to $63.00 - GuruFocus
Barclays Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
ANAB Maintained by UBS -- Price Target Lowered to $60 - GuruFocus
AnaptysBio (ANAB) Shares Rise Following Successful Spinoff of Fi - GuruFocus
AnaptysBio rises after First Tracks spinoff (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio rises after completing First Tracks spinoff
12 Health Care Stocks Moving In Monday's Intraday Session
$ANAB stock is down 26% today. Here's what we see in our data. - Quiver Quantitative
AnaptysBio (NASDAQ:ANAB) Shares Gap Down - Here's What Happened - MarketBeat
AnaptysBio Announces Completion of Spin-Off and Focus on Managing Jemperli and Imsidolimab Royalties for Shareholder Value - Quiver Quantitative
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
After spin-off, Anaptys shifts to royalty-only model with $140M-$145M cash - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session
Discipline and Rules-Based Execution in ANAB Response - Stock Traders Daily
Four Biotech Stocks Near Buy Points As Earnings Season Kicks In
AnaptysBio, Inc. $ANAB Shares Sold by JPMorgan Chase & Co. - MarketBeat
SG Americas Securities LLC Acquires Shares of 10,428 AnaptysBio, Inc. $ANAB
$ANAB stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Director John Schmid Sells 20,645 Shares of Stock
Director Susannah Gray at AnaptysBio (ANAB) submits initial Form 3 - Stock Titan
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts
ANAPTYSBIO (ANAB) reports ownership of 100 First Tracks Biotherapeutics shares - Stock Titan
[Form 4] ANAPTYSBIO, INC Insider Trading Activity - Stock Titan
ANAB SEC Filings - Anaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 17,679 Shares
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care Stocks Retreat Friday Afternoon
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
First Tracks targets $180M cash at launch after $145M financing - Stock Titan
AnaptysBio Announces Spin-Off of First Tracks Biotherapeutics with Distribution Date Set for April 20, 2026 - Quiver Quantitative
Anaptys holders get 1-for-1 new biotech shares in April spin-off - Stock Titan
AnaptysBio Announces Spin-Off of First Tracks Biotherapeutics with Stock Repurchase Plan and Board Update - Quiver Quantitative
After its biotech spin-off, Anaptys plans to buy back $100M in stock - Stock Titan
AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume – Should You Buy?
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Brokerages
Research Analysts Issue Forecasts for AnaptysBio Q1 Earnings
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress
HC Wainwright Predicts AnaptysBio FY2030 Earnings
AnaptysBio (NASDAQ:ANAB) Sets New 12-Month High on Analyst Upgrade
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates
AnaptysBio GAAP EPS of $1.58 beats by $0.71, revenue of $108.25M beats by $21.16M
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Anaptys splits royalties and biopharma arm as Jemperli sales rise - Stock Titan
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge?
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? - Yahoo Finance
Anaptys Announces Participation at Upcoming Investor Conferences